Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A trial of Takeda's oral antidiabetic Actos has shown the drug to be capable of significantly reducing the incidence of stroke by almost 50% in high-risk patients with type 2 diabetes.
Subscribe to our email newsletter
New analyses from the landmark PROactive study examined the effects of Actos on the risk of stroke and other cardiovascular outcomes in high-risk patients with type 2 diabetes, with and without prior stroke. Pre-specified study endpoints included all-stroke and cardiovascular disease death, myocardial infarction (MI) or stroke.
According to the results, there were statistically significant benefits of Actos in patients who had suffered a prior stroke. The incidence of recurrent stroke was reduced by 47% and the combined risk of death, MI or stroke was reduced by 28%.
There was no effect of Actos on subsequent strokes in patients who had never experienced a stroke.
“These results are very encouraging news for people with type 2 diabetes because they demonstrated that Actos reduced the incidence of strokes in patients who had already experienced a stroke from 10.2% down to 5.6 %, translating to a risk reduction of almost 50%,” said Robert Wilcox, professor in the department of cardiovascular medicine at University Hospital, Nottingham, UK.